이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

SMP-656 for HER2-Positive Advanced Breast Cancer

2026년 7월 22일 업데이트: Chengdu SciMount Pharmatech Co., Ltd.

A Randomized, Open-Label, Dose-Optimization Phase II Clinical Trial to Evaluate the Efficacy and Safety of Single-Agent SMP-656 in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Progressed After Prior Treatment With HER2-Targeted Topoisomerase Inhibitor ADCs

The goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) treatment. It will also evaluate the safety of SMP-656 and identify the optimal dose for future trials. The main questions it aims to answer are:

What is the objective tumor response rate (DOR, PFS, DCR, OS) of two different dose regimens of intravenous SMP-656? What are the side effects and safety risks of these two SMP-656 dose regimens? Which dose level achieves the best balance of anti-cancer activity and tolerability? This is a randomized, open-label, dose-optimization Phase II clinical trial. Participants will be randomly assigned 1:1 to receive one of two fixed doses of SMP-656 given intravenously once every 3 weeks.

Participants will:

Complete screening tests within 28 days before the first SMP-656 infusion to confirm eligibility Receive study treatment every 3 weeks until cancer progression, intolerable side effects, withdrawal, or other stopping criteria Have regular tumor imaging scans, physical exams, vital sign checks, and blood tests to monitor tumor response and safety Attend a safety follow-up visit 30 days after the last dose of SMP-656 Complete longer-term survival follow-up after the 30-day safety check Provide optional blood and tumor tissue samples for additional research studies

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

This is a randomized, open-label, dose-optimization Phase II clinical trial to assess the efficacy and safety of single-agent SMP-656 in patients with HER2-positive unresectable locally advanced or metastatic breast cancer who progressed after prior HER2-targeted topoisomerase inhibitor ADC therapy.

The trial plans to enroll approximately 45-60 participants. Eligible participants must have received one prior HER2-targeted topoisomerase inhibitor ADC (e.g., DS-8201 or other ADCs with topoisomerase inhibitor payloads) and experienced disease progression after a maximum of three lines of standard systemic therapy for recurrent/metastatic disease (single-agent endocrine therapy excluded).

Two dose cohorts selected based on Phase I data: 2.0 mg/kg and 2.2 mg/kg. Participants will be randomized 1:1 to each dose cohort, with 15 subjects enrolled per cohort in Stage 1. An interim analysis will be conducted after Stage 1 enrollment completion:

  1. If statistically significant differences in safety/efficacy between cohorts are identified that materially impact risk-benefit assessment, the inferior cohort will be closed, and the superior cohort will accrue an additional 15 subjects to complete the trial.
  2. If no meaningful inter-cohort differences are observed, randomization will continue 1:1 with an additional 15 subjects per cohort.

The investigational product will be administered intravenously once every 3 weeks (Q3W). All participants will receive long-term treatment until the first occurrence of any of the following events: intolerable toxicity, disease progression (judged by the investigator that further treatment cannot provide clinical benefit), loss to follow-up, death, voluntary withdrawal, or study completion/early termination of the trial, whichever comes first.

A Safety Review Committee (SRC) will be established for this trial. Based on the results of interim analysis assessments, the SRC shall judge and determine the further research of each dose group, and make decisions on the key clinical trial doses.

The study consists of a screening period (from the time participants sign the informed consent form up to prior to the first study drug administration, with a maximum duration of 28 days), a treatment period (from the first study drug administration to permanent discontinuation of study drug), and a follow-up period (post-discontinuation safety follow-up and survival follow-up).

During the treatment period, all participants shall undergo tumor imaging assessments every 6 weeks (±7 days) starting from the first dose administration. Imaging assessments will not be affected by interrupted or delayed study drug administration. Investigators will assess antitumor efficacy in accordance with Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Assessments will continue until the earliest occurrence of any of the following events: disease progression, withdrawal of informed consent, loss to follow-up, death, initiation of new antitumor therapy, or trial conclusion (including trial completion and early trial termination), whichever comes first.

Safety Follow-up All participants shall complete a safety follow-up visit at 30 days ± 7 days after the last dose of the investigational product.

If the End of Treatment (EOT) visit for early discontinuation or treatment completion coincides with the scheduled safety follow-up timepoint, duplicate assessments are not required.

If the actual completion date of the early discontinuation/treatment completion (EOT) visit falls beyond the scheduled safety follow-up window due to objective reasons (e.g., delayed dosing), duplicate assessments are also not required. Failure to complete the dedicated safety follow-up in such circumstances shall not be deemed a protocol deviation (PD).

Survival Follow-up After completion of the safety follow-up, investigators will collect survival information for all participants every 3 months (±14 days) via telephone interviews, review of participants' medical records or outpatient medical files. Survival follow-up will continue until any of the following occurs: withdrawal of informed consent by the participant, loss to follow-up, death, or trial termination.

연구 유형

중재적

등록 (추정된)

60

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

  • 중국
    • Anhui
      • Hefei, Anhui, 중국
        • The Second Affiliated Hospital of Anhui Medical University
        • 수석 연구원:
          • Fanfan Li
        • 연락하다:
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국
        • Beijing Cancer Hospital
        • 수석 연구원:
          • Huiping Li
        • 연락하다:
      • Beijing, Beijing Municipality, 중국
        • Cancer Hospital, Chinese Academy of Medical Sciences
        • 수석 연구원:
          • Binghe Xu
        • 연락하다:
    • Guangdong
      • Guangzhou, Guangdong, 중국
        • Sun Yat-Sen University Cancer Center
        • 수석 연구원:
          • Shusen Wang
        • 연락하다:
    • Hebei
      • Shijiazhuang, Hebei, 중국
        • The Fourth Hospital of Hebei Medical University
        • 연락하다:
        • 수석 연구원:
          • Yunjiang Liu
    • Henan
      • Zhengzhou, Henan, 중국
        • Henan Provincial People's Hospital
        • 연락하다:
        • 수석 연구원:
          • Jinlong Hu
    • Hubei
      • Wuhan, Hubei, 중국
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • 연락하다:
        • 수석 연구원:
          • Yanxia Zhao
      • Wuhan, Hubei, 중국
        • Zhongnan Hospital of Wuhan University
        • 수석 연구원:
          • Haijun Yu
        • 연락하다:
    • Hunan
      • Changsha, Hunan, 중국
        • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
        • 수석 연구원:
          • Quchang Ouyang
        • 연락하다:
    • Jiangsu
      • Nanjing, Jiangsu, 중국
        • Zhongda Hospital, Southeast University
        • 연락하다:
        • 수석 연구원:
          • Haijun Zhang
    • Liaoning
      • Shenyang, Liaoning, 중국
        • Liaoning cancer Hospital & Institute
        • 수석 연구원:
          • Tao Sun
        • 연락하다:
    • Shandong
      • Jinan, Shandong, 중국
        • Shandong Cancer Hospital and Institute
        • 수석 연구원:
          • Huihui Li
        • 연락하다:
    • Shanxi
      • Xi’an, Shanxi, 중국
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • 수석 연구원:
          • Jin Yang
        • 연락하다:
    • Sichuan
      • Chengdu, Sichuan, 중국
        • Sichuan Cancer Hospital & Institute
        • 수석 연구원:
          • Junjie Li
        • 연락하다:
    • Zhejiang
      • Hangzhou, Zhejiang, 중국
        • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
        • 수석 연구원:
          • Xian Wang
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Voluntarily participate in this clinical trial, understand and comply with study procedures, and provide written informed consent voluntarily;
  2. Female patients aged ≥ 18 years at the time of signing the informed consent form;
  3. Patients with histologically or cytologically confirmed unresectable HER2-positive locally advanced or metastatic breast cancer, regardless of hormone receptor (HR) status;
  4. HER2-positive status confirmed by testing at the study center or an accredited laboratory, where HER2 positivity is defined as IHC 3+, or IHC 2+ with positive fluorescence in situ hybridization (FISH+) results;
  5. Patients with HER2-positive locally advanced or metastatic breast cancer who have received prior treatment with one TOP inhibitor ADC targeting HER2 (e.g., DS-8201 and other ADCs with topoisomerase inhibitor payloads), and have experienced disease progression after no more than three lines of standard therapy for recurrent or metastatic disease; 1) Endocrine monotherapy is excluded from the abovementioned standard therapy lines; 2) Disease recurrence occurring within 12 months following neoadjuvant or adjuvant chemotherapy will be regarded as progression after first-line standard therapy;
  6. Have at least one measurable target lesion per the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) ;
  7. ECOG performance status 0-1;
  8. Expected survival ≥ 3 months;

  9. Bone marrow, hepatic, renal and coagulation function shall be deemed adequate based on laboratory tests performed within 7 days prior to the first dose of the investigational product. Blood transfusion or growth factor supportive therapy is prohibited within 14 days before the first administration of the investigational product：

    • Bone marrow function: absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count (PLT) ≥ 80 × 10⁹/L; hemoglobin (Hb) ≥ 90 g/L;
    • Hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total serum bilirubin (TBIL) ≤ 1.5 × ULN, with the following exceptions;
    • For participants with confirmed liver metastases: AST and/or ALT ≤ 5 × ULN;
    • For participants diagnosed with Gilbert's syndrome: TBIL ≤ 3 × ULN;
    • Serum albumin ≥ 30 g/L;
    • Renal function: Creatinine clearance (CrCL) ≥ 50 mL/min (calculated via the Cockcroft-Gault formula), OR serum creatinine ≤ 1.5 × ULN;
    • Coagulation function: International Normalized Ratio (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
  10. Women of childbearing potential (WOCBP) must agree to use highly effective contraception or maintain abstinence from the time of informed consent signature through 6 months after the last administration of the investigational product；For WOCBP, serum pregnancy testing performed within 7 days prior to the first dose of the investigational product must yield a negative result.

Exclusion Criteria:

  1. Patients with inflammatory breast cancer;
  2. Have received eribulin in prior lines of therapy;
  3. Have received prior treatment with ADCs carrying tubulin inhibitor payloads for recurrent or metastatic disease;
  4. Prior anti-tumor therapy consisting of utidelone or vinca alkaloids as the last regimen;
  5. Patients with a known history of severe hypersensitivity to inetetamab, SMP-656, or any of their excipients;
  6. Patients with meningeal metastases;
  7. Patients with active central nervous system (CNS) metastases are excluded, with the following exception: symptomatic CNS metastases limited to supratentorial region and/or cerebellum (i.e., no midbrain, pons, medulla oblongata or spinal cord metastases) that have received local therapy, with neurological symptoms stabilized for at least 2 weeks prior to the first dose of investigational product, and no requirement for steroid therapy or receiving prednisone ≤10 mg/day (or equivalent corticosteroids) ;
  8. Patients diagnosed with any other malignancy (other than the study tumor type) within 5 years prior to the first dose of the investigational product, except curatively treated localized malignancies such as basal cell carcinoma of the skin;
  9. Previous, current or suspected interstitial lung disease (ILD), drug-induced interstitial lung disease; or clinically significant active pneumonia identified at screening; or radiation pneumonitis, or other severe pulmonary disorders impairing respiratory function, which in the Investigator's judgment may interfere with the detection or management of investigational product-related pulmonary toxicity;
  10. Patients with a clinically significant history of cardiovascular disease, including but not limited to： (1) Left ventricular ejection fraction (LVEF) < 50%; congestive heart failure with New York Heart Association (NYHA) functional class > 2; (2) Have experienced myocardial infarction, unstable angina, severe pericardial disease or severe myocardial disease within the previous 6 months; (3) Presence of cardiac valve regurgitation or stenosis requiring therapeutic intervention; (4) Any supraventricular or ventricular arrhythmia requiring treatment or intervention; poorly controlled malignant arrhythmias despite medication; complete left bundle branch block, second-degree or third-degree atrioventricular block; (5) QTc interval > 470 ms at screening (for female participants), or known family history of long QT syndrome; (6) Uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg despite antihypertensive medication, or prior history of hypertensive crisis or hypertensive encephalopathy) ;
  11. History of arterial or venous thromboembolic events within 6 months prior to the first dose of the investigational product, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism;
  12. Participants with uncontrollable pleural effusion, pericardial effusion or ascites as judged by the Investigator, which requires repeated drainage once every two weeks or more frequently. Participants with indwelling pleural catheters are permitted to enroll;
  13. Have received live attenuated vaccines within 4 weeks prior to the first dose of the investigational produc, or plan to receive live attenuated vaccines during the study;
  14. Patients with severe infection within 4 weeks prior to the first dose of the investigational product, including but not limited to bacteremia or severe pneumonia requiring hospitalization; or active infection with CTCAE Grade ≥2 requiring systemic antibiotic therapy within 2 weeks before the first dose (prophylactic antibiotics excluded) ;
  15. Patients meeting any of the following criteria will be excluded: patients with active hepatitis B or hepatitis C；For patients positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), enrollment is permitted only if quantitative hepatitis B virus DNA (HBV-DNA) is below the upper limit of normal (ULN) of the study site laboratory；For patients positive for hepatitis C antibody (HCV-Ab), enrollment is permitted only if HCV RNA is below the ULN of the study site laboratory；Positive human immunodeficiency virus (HIV) antibody test; active syphilis infection; active tuberculosis infection;
  16. Patients with unresolved prior anti-tumor treatment-related toxicities (alopecia excluded) remaining at Grade >1 or not recovered to baseline, except adverse events (AEs) deemed not to pose a safety risk by the Investigator;
  17. Patients with Grade ≥2 peripheral neuropathy; or prior history of Grade ≥3 neurotoxicity / peripheral neuropathy; or permanent discontinuation of previous anti-tumor treatment due to neurotoxicity or peripheral neuropathy;
  18. Patients with a history of allogeneic stem cell transplantation or solid organ transplantation, or those planning to receive allogeneic stem cell transplantation or solid organ transplantation during the study;
  19. Patients who have participated in any other clinical trial within 4 weeks or 5 half-lives prior to the first dose of the investigational product, whichever is shorter;
  20. Patients who received radiotherapy within 4 weeks prior to the first dose of the investigational product are excluded, except palliative radiotherapy administered for symptom control within 2 weeks before the first dose of investigational product;
  21. Patients who received systemic anti-tumor therapy within 4 weeks prior to the first dose of the investigational product are excluded, except for the following： 1) Enrollment is permitted only if at least 6 weeks have elapsed between the completion of prior nitrosourea or mitomycin chemotherapy and the first dose of the investigational product; 2) Enrollment is allowed only if a minimum of 1 week has passed between the discontinuation of prior small-molecule targeted therapy and the first dose of the investigational product; 3) Enrollment is permitted only if a minimum of 2 weeks have elapsed between discontinuation of prior traditional Chinese medicine with anti-tumor effects and the first dose of the investigational product;
  22. articipants who have undergone major surgery within 4 weeks prior to the first dose of the investigational product, or are expected to receive major surgery during the study period (diagnostic surgery excluded); those who received diagnostic or minimally invasive surgery within 1 week before the first dose are also excluded;
  23. Patients requiring long-term treatment with corticosteroids or immunosuppressive agents (e.g., active autoimmune diseases requiring systemic therapy). Replacement therapies such as thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency are permitted;
  24. Prior documented history of neurological or psychiatric disorders, including epilepsy or dementia;
  25. Female Patients who are pregnant, breastfeeding, or planning to become pregnant during the study;
  26. Patients with severe concomitant diseases that may compromise patient safety or interfere with study completion as judged by the Investigator (e.g., severe hypertension, diabetes mellitus, thyroid disorders), or any other conditions deemed inappropriate for study participation by the Investigator .

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SMP-656 2.0 mg/kg
SMP-656 2.0 mg/kg Q3W
의약품: SMP-656 Injection
SMP-656 injection administered via intravenous infusion at a dose of 2.0 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.
의약품: SMP-656 Injection
SMP-656 injection administered via intravenous infusion at a dose of 2.2 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.
실험적: SMP-656 2.2 mg/kg
SMP-656 2.2 mg/kg Q3W
의약품: SMP-656 Injection
SMP-656 injection administered via intravenous infusion at a dose of 2.0 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.
의약품: SMP-656 Injection
SMP-656 injection administered via intravenous infusion at a dose of 2.2 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (ORR) assessed by Independent Review Committee (IRC)
기간: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
ORR is the percentage of evaluable patients with an IRC-assessed response of complete response (CR) or partial response (PR) per RECIST v1.1.
From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
Recommended Dose in Pivotal Clinical Trials
기간: Through study completion, up to 24 months from first dose
Determination of pivotal trial recommended dose based on drug exposure, efficacy, and safety profiles across different dose levels.
Through study completion, up to 24 months from first dose

2차 결과 측정

결과 측정
측정값 설명
기간
ORR assessed by Investigators
기간: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
Investigator-assessed ORR is the percentage of evaluable patients with a confirmed investigator-assessed response of CR or PR per RECIST v1.1.
From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
Duration of Response (DOR)
기간: From first confirmed objective response (CR/PR) up to 24 months from first dose
DOR is the time from the date of first documented confirmed objective response (CR or PR per RECIST v1.1) until the date of disease progression or death.
From first confirmed objective response (CR/PR) up to 24 months from first dose
Progression-Free Survival (PFS)
기간: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
PFS is the time from the date of first dose until the date of objective radiographic disease progression or death (by any cause in the absence of progression).
From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
Disease Control Rate (DCR)
기간: Up to 24 months from first dose
DCR is the investigator-assessed percentage of evaluable participants with confirmed CR (complete response), PR (partial response), or SD (stable disease) per RECIST v1.1.
Up to 24 months from first dose
Overall Survival (OS)
기간: From treatment initiation until death from any cause, assessed up to 60 months.
OS is the time from the date of first dose until the date of death by any cause.
From treatment initiation until death from any cause, assessed up to 60 months.
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) / Serious Adverse Events (SAEs)
기간: From enrollment through 30 days after last study drug administration, up to 24 months
Frequency, type, and maximum grade of all AEs and SAEs graded per NCI CTCAE Version 6.0
From enrollment through 30 days after last study drug administration, up to 24 months
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
기간: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Maximum Plasma concentration (Cmax) of SMP-656 and total anti-HER2 antibody is assessed.
Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
기간: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Maximum Plasma Concentration (Cmax) of free eribulin is assessed.
Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Time to Maximum Serum Concentration (Tmax) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
기간: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Time to maximum serum concentration (Tmax) of SMP-656 and total anti-HER2 antibody is assessed.
Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Time to Maximum Serum Concentration (Tmax) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
기간: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Time to maximum serum concentration (Tmax) of free eribulin is assessed.
Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
기간: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Area under the concentration-time curve (AUC) from dosing until 21 days (AUC21d) and the last quantifiable concentration (AUClast) of SMP-656 and total anti-HER2 antibody are assessed.
Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer
기간: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Area under the concentration-time curve (AUC) from dosing until 21 days (AUC21d) and the last quantifiable concentration (AUClast) of free eribulin is assessed.
Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).
Exposure-Efficacy and Exposure-Safety (E-R) Relationships
기간: Each cycle is 21 days. Exposure, efficacy and safety data are collected during Cycle 1-5 and subsequent odd maintenance cycles, at the occurrence of SAEs or Grade ≥3 TRAEs, and through 30 (±7) days following the last study dose. (up to 24 months)
Exposure-response (E-R) analysis evaluating correlations between exposure of conjugated SMP-656, total antibody, free eribulin and efficacy/safety endpoints.
Each cycle is 21 days. Exposure, efficacy and safety data are collected during Cycle 1-5 and subsequent odd maintenance cycles, at the occurrence of SAEs or Grade ≥3 TRAEs, and through 30 (±7) days following the last study dose. (up to 24 months)
Exposure-Efficacy and Exposure-Safety (E-R) Relationships
기간: From Cycle 1 through all odd maintenance cycles, 30 days after last dose, and at onset of serious adverse event or Grade ≥3 treatment-related adverse event
Exposure-response (E-R) analysis evaluating correlations between exposure of conjugated SMP-656, total antibody, free eribulin and efficacy/safety endpoints.
From Cycle 1 through all odd maintenance cycles, 30 days after last dose, and at onset of serious adverse event or Grade ≥3 treatment-related adverse event
Immunogenicity of SMP-656
기간: Each cycle is 21 days. Immunogenicity sampling is conducted within 1 hour pre-dose on C1D1, C2D1, C3D1, C5D1, and every 4 subsequent cycles. Additional sampling is done for SAEs/Grade ≥3 TRAEs, and 30 days after the last dose. (up to 24 months)
Incidence and magnitude of anti-drug antibody responses to SMP-656
Each cycle is 21 days. Immunogenicity sampling is conducted within 1 hour pre-dose on C1D1, C2D1, C3D1, C5D1, and every 4 subsequent cycles. Additional sampling is done for SAEs/Grade ≥3 TRAEs, and 30 days after the last dose. (up to 24 months)

기타 결과 측정

결과 측정
측정값 설명
기간
Genomic and Microenvironment Molecular Alterations Associated With SMP-656 Resistance
기간: Baseline and end-of-treatment (EOT) visit. EOT sampling is performed within 7 days after treatment discontinuation and prior to any new antitumor therapy, up to 24 months from first dose.
Baseline and post-treatment genomic, circulating biomarker and tissue spatial microenvironment profiles of blood and tumor samples, including ctDNA, circulating proteins, exosomes, and tissue microenvironment features.
Baseline and end-of-treatment (EOT) visit. EOT sampling is performed within 7 days after treatment discontinuation and prior to any new antitumor therapy, up to 24 months from first dose.
Multi-Omics Biomarker Profiles Correlated With Clinical Efficacy and Prognosis
기간: Baseline and EOT visit. EOT sampling is performed within 7 days after treatment discontinuation and prior to any new antitumor therapy, up to 24 months from first dose.
Multi-omics profiles of blood and tumor samples, including ctDNA, plasma proteomics, single-exosome profiling, tissue spatial transcriptomics/proteomics, and tissue genomic features.
Baseline and EOT visit. EOT sampling is performed within 7 days after treatment discontinuation and prior to any new antitumor therapy, up to 24 months from first dose.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Chengdu SciMount Pharmatech Co., Ltd.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 16일

기본 완료 (추정된)

2027년 7월 7일

연구 완료 (추정된)

2027년 10월 20일

연구 등록 날짜

최초 제출

2026년 7월 13일

QC 기준을 충족하는 최초 제출

2026년 7월 22일

처음 게시됨 (실제)

2026년 7월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 22일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • SMP-656-201

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

전이성 유방암에 대한 임상 시험

SMP-656 Injection에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Myanmar

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

구독하다